Pathology

Digital Pathology market set to grow at 11% CAGR to reach $ 1.54 billion by 2030; Companies deploying innovative, data-driven alogithms & business models to grow market

Retrieved on: 
Monday, August 2, 2021

Pathology is an area where digitization and automation can bring about significant benefits to patients, physicians, pathologists & labs/hospitals.

Key Points: 
  • Pathology is an area where digitization and automation can bring about significant benefits to patients, physicians, pathologists & labs/hospitals.
  • Faster turnaround time leading to benefits for labs, patients & clinicians
    These benefits, coupled with favourable regulatory environment and reimbursement, is expected to drive the market growth.
  • The Global Digital Pathology Market is estimated to reach $ 1.54 billion by 2030 growing with a CAGR of 11% from 2020-2030.
  • The current Digital Pathology market is dominated by Scanners which are used to digitally scan the samples.

Epygenix Therapeutics Receives U.S. FDA Orphan Drug Designation for EPX-200 in Lennox-Gastaut Syndrome

Retrieved on: 
Monday, August 2, 2021

PARAMUS, N.J., Aug. 2, 2021 /PRNewswire/ --Epygenix Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to EPX-200 for the treatment of Lennox-Gastaut Syndrome (LGS).

Key Points: 
  • PARAMUS, N.J., Aug. 2, 2021 /PRNewswire/ --Epygenix Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to EPX-200 for the treatment of Lennox-Gastaut Syndrome (LGS).
  • "Granting Orphan Drug Designation for LGS to EPX-200 is one of the company's significant development milestones, because the Company is expanding targeted indications to multiple refractory epilepsies, including LGS.
  • The FDA's ODD grant to EPX-200 for LGS recognizes the significance of EPX-200 as a drug candidate for these patients.
  • EPX-200 also has been reported to have anti-seizure effects based on the result from small number of patients.

Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome

Retrieved on: 
Monday, August 2, 2021

Patients also suffer with life-threatening medically intractable seizures that may increase the risk of SUDEP (Sudden Unexplained Death in Epilepsy), seizure-related accidents such as drowning, or infections.

Key Points: 
  • Patients also suffer with life-threatening medically intractable seizures that may increase the risk of SUDEP (Sudden Unexplained Death in Epilepsy), seizure-related accidents such as drowning, or infections.
  • Dr. Hahn-Jun Lee, M.Sc., Ph.D., President and CEO of Epygenix Therapeutics, Inc. stated that the EMA's Orphan Medicinal Product Designation to EPX-200 is very important, as EMA recognizes the significant potential benefit of EPX-200 for DS treatment.
  • The Orphan Medicinal Product Designation from EMA for EPX-200 brings us one step closer to such positionto bring our drugs to patients in Europe more efficiently."
  • EPX-200 has already been successfully tested in five Dravet Syndrome patients at the University of Colorado Hospital, where it showed an ability to reduce seizure frequency in a small compassionate use trial.

Transmission Electron Microscope Market | $ 287.79 Mn growth expected during 2020-2024 | Technavio

Retrieved on: 
Thursday, July 29, 2021

Buy our market report now to gain access to detailed analysis on the transmission electron microscope market: https://www.technavio.com/talk-to-us?report=IRTNTR40642

Key Points: 
  • Buy our market report now to gain access to detailed analysis on the transmission electron microscope market: https://www.technavio.com/talk-to-us?report=IRTNTR40642
    Transmission Electron Microscope Market 2020-2024: Vendor Analysis and Scope
    To help businesses improve their market position, the transmission electron microscope market provides a detailed analysis of around 25 vendors operating in the market.
  • The report also covers the following areas:
    The development of new forms of transmission electron microscopes is likely to emerge as one of the primary drivers of the market.
  • However, the high cost and heavy excise duty of transmission electron microscopes may threaten the growth of the market.
  • Backed with competitive intelligence and benchmarking, our research reporton the transmission electron microscope market is designed to provide entry support, customer profile & M&As as well as go-to-market strategy support.

New CAP Publication Focuses on Modern Surgical Pathology for Quality Patient Care

Retrieved on: 
Wednesday, July 28, 2021

"Grossing, Staging, and ReportingAn Integrated Manual of Modern Surgical Pathology, released this month from the College of American Pathologists (CAP) Press, guides readers through producing a comprehensive, succinct pathology report that emphasizes the factors that directly determine the quality of patient care.

Key Points: 
  • "Grossing, Staging, and ReportingAn Integrated Manual of Modern Surgical Pathology, released this month from the College of American Pathologists (CAP) Press, guides readers through producing a comprehensive, succinct pathology report that emphasizes the factors that directly determine the quality of patient care.
  • Dr. Zhai had the opportunity to collaborate with more than 40 experienced practicing pathologists from various practice settings.
  • With more amazing technology emerging and being applied in daily practice, its important to remember our daily and routine pathology reports are still the cornerstones of modern medicine.
  • With more than 400 images, the 288-page book is available in softcover ($76 for CAP members, $95 for others) and ebook ($72) formats.

Explore Developments in Timely Diagnosis Technologies on Advancements TV Series

Retrieved on: 
Monday, July 26, 2021

JUPITER, Fla., July 26, 2021 /PRNewswire-PRWeb/ -- Scheduled to broadcast Q4/2021, the award-winning series, Advancements with Ted Danson, will focus on supporting technologies for timely diagnosis.

Key Points: 
  • JUPITER, Fla., July 26, 2021 /PRNewswire-PRWeb/ -- Scheduled to broadcast Q4/2021, the award-winning series, Advancements with Ted Danson, will focus on supporting technologies for timely diagnosis.
  • In this segment, viewers will learn about ROSE an established Rapid On-site Evaluation procedure for evaluation of biopsy specimens at the time of collection.
  • Hearing from experts in the field, audiences will see how ROSE helps experienced Cytopathologists determine if the content is adequate to provide a diagnosis.
  • For more information, visit: http://www.roseaid.com
    About Advancements and DMG Productions:
    The Advancements series is an information-based educational show targeting recent advances across a number of industries and economies.

PathAI enters into clinical diagnostics through acquisition of Poplar Healthcare Management

Retrieved on: 
Monday, July 26, 2021

BOSTON and MEMPHIS, Tenn., July 26, 2021 /PRNewswire/ -- PathAI, a global provider of artificial intelligence-powered technology for pathology, announced their acquisition of Poplar, the management service organization for Poplar Healthcare PLLC, an industry-leading independent anatomic pathology laboratory services provider.

Key Points: 
  • BOSTON and MEMPHIS, Tenn., July 26, 2021 /PRNewswire/ -- PathAI, a global provider of artificial intelligence-powered technology for pathology, announced their acquisition of Poplar, the management service organization for Poplar Healthcare PLLC, an industry-leading independent anatomic pathology laboratory services provider.
  • Poplar's facilities, management team and 350 employees now comprise PathAI's diagnostics division, which will remain based in Memphis.
  • Together, PathAI and Poplar will be investing to further digitize the Poplar laboratory workflow, and leverage PathAI's image analysis and algorithm development capabilities to unlock new clinical applications.
  • In partnering with Poplar Healthcare, PathAI adds traditional laboratory services at scale to its already powerful suite of AI-powered pathology tools.

Explore Developments in Timely Diagnosis Technologies on Advancements TV Series

Retrieved on: 
Monday, July 26, 2021

JUPITER, Fla., July 24, 2021 /PRNewswire-PRWeb/ -- Scheduled to broadcast Q4/2021, the award-winning series, Advancements with Ted Danson, will focus on supporting technologies for timely diagnosis.

Key Points: 
  • JUPITER, Fla., July 24, 2021 /PRNewswire-PRWeb/ -- Scheduled to broadcast Q4/2021, the award-winning series, Advancements with Ted Danson, will focus on supporting technologies for timely diagnosis.
  • In this segment, viewers will learn about ROSE an established Rapid On-site Evaluation procedure for evaluation of biopsy specimens at the time of collection.
  • Hearing from experts in the field, audiences will see how ROSE helps experienced Cytopathologists determine if the content is adequate to provide a diagnosis.
  • For more information, visit: http://www.roseaid.com
    About Advancements and DMG Productions:
    The Advancements series is an information-based educational show targeting recent advances across a number of industries and economies.

Synergy Laboratories Hires Dr. Tyler Jones as New Pathologist

Retrieved on: 
Tuesday, July 20, 2021

Synergy Laboratories in Mobile, AL hires Dr. Tyler Jones as a new Pathologist at Pathology Laboratory Associates INC.

Key Points: 
  • Synergy Laboratories in Mobile, AL hires Dr. Tyler Jones as a new Pathologist at Pathology Laboratory Associates INC.
    Dr. Tyler Jones is a graduate of Brigham Young University in Provo, UT, and graduated medical school at Ross University School of Medicine.
  • Dr. Jones stated, I am extremely excited to join the Synergy family!
  • Synergy Laboratories is a full-service diagnostic laboratory that utilizes various innovative platforms to improve patient care.
  • Synergy Laboratories is a high-complexity CLIA and COLA-certified lab with one of the Southeast's most extensive COVID-19 testing facilities.

Worldwide Digital Pathology Industry to 2026 - Applications of Digital Pathology in Clinical Research is Driving Growth

Retrieved on: 
Monday, July 19, 2021

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Digital Pathology Market Report.

Key Points: 
  • In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Digital Pathology Market Report.
  • The global digital pathology market by revenue is expected to grow at a CAGR of over 10% during the period 2020-2026.
  • The incorporation of artificial intelligence further extends the limits of pathology studies and data management, helping to increase the acceptance of digital pathology.
  • The global digital pathology academic research and teaching market is expected to reach USD 598.58 million by 2026.